A number of companies are trying to improve cancer immunotherapy by disrupting the ways that tumors evade the immune system. Tempest Therapeutics is now joining that group with $70 million in financing to advance its drug pipeline. Tempest is a spinoff from a drug discovery unit supported by Versant Ventures, which co-led the Series B […]
Original Article: Tempest Therapeutics Debuts with $70M to Bring Cancer Drugs to Clinic